Claims for Patent: 10,767,222

Summary for Patent: 10,767,222

Title:	Compositions and methods for detecting rare sequence variants
Abstract:	In some aspects, the present disclosure provides methods for identifying sequence variants in a nucleic acid sample. In some embodiments, a method comprises identifying sequence differences between sequencing reads and a reference sequence, and calling a sequence difference that occurs in at least two different circular polynucleotides, such as two circular polynucleotides having different junctions, as the sequence variant. In some aspects, the present disclosure provides compositions and systems useful in the described methods.
Inventor(s):	Shengrong Lin, Zhaohui Sun, Grace Qizhi ZHAO, Paul Ling-Fung TANG
Assignee:	Accuragen Holdings Ltd
Application Number:	US15/102,241

Details for Patent 10,767,222

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009		2034-12-11
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	April 01, 2011		2034-12-11
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	August 20, 2020		2034-12-11

International Patent Family for US Patent 10,767,222

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017062863
World Intellectual Property Organization (WIPO)	2015089333
United States of America	2025290136
United States of America	2023416819
United States of America	2023287485
United States of America	2021054449
United States of America	2021002716